Galiximab

Galiximab is a monoclonal antibody that was under development for the treatment of certain types of cancer, specifically non-Hodgkin lymphoma. It targets the CD80 molecule, a protein expressed on the surface of some B-cells and tumor cells, which is involved in the regulation of immune response.

Development and Mechanism

Galiximab is a primatized antibody, meaning it is a hybrid molecule composed of both human and primate antibody sequences. This design aims to reduce the likelihood of the human immune system recognizing the antibody as foreign and developing an antibody response against it, which can limit the therapeutic efficacy and increase the risk of adverse effects.

The mechanism of action of galiximab involves binding to the CD80 molecule on the surface of B-cells. CD80 plays a critical role in the activation of T-cells, which are essential for immune surveillance against tumors. By targeting CD80, galiximab may help inhibit the growth of B-cell lymphomas, which rely on these interactions for survival and proliferation.

Clinical Trials

Galiximab was evaluated in several clinical trials, often in combination with other chemotherapy agents. These studies aimed to assess its safety and efficacy in patients with non-Hodgkin lymphoma. However, as of the last updates, it has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use.

Current Status

Research on galiximab has been limited, and it is not currently available as a treatment option. The development may have been discontinued or paused due to various factors, including clinical trial results, strategic decisions by the developing company, or other regulatory issues.

See Also

• Monoclonal antibodies
• Immunotherapy
• Cancer treatment